Literature DB >> 12687606

Protein-protein interactions as a target for drugs in proteomics.

Alexander I Archakov1, Vadim M Govorun, Alexander V Dubanov, Yuri D Ivanov, Alexander V Veselovsky, Paul Lewi, Paul Janssen.   

Abstract

Protein-protein interactions play a central role in numerous processes in the cell and are one of the main fields of functional proteomics. This review highlights the methods of bioinformatics and functional proteomics of protein-protein interaction investigation. The structures and properties of contact surfaces, forces involved in protein-protein interactions, kinetic and thermodynamic parameters of these reactions were considered. The properties of protein contact surfaces depend on their functions. The contact surfaces of permanent complexes resemble domain contacts or the protein core and it is reasonable to consider such complex formation as a continuation of protein folding. Characteristics of contact surfaces of temporary protein complexes share some similarities with active sites of enzymes. The contact surfaces of the temporary protein complexes have unique structure and properties and they are more conservative in comparison with active site of enzymes. So they represent prospective targets for a new generation of drugs. During the last decade, numerous investigations were undertaken to find or design small molecules that block protein dimerization or protein(peptide)-receptor interaction, or, on the contrary, to induce protein dimerization.

Mesh:

Substances:

Year:  2003        PMID: 12687606     DOI: 10.1002/pmic.200390053

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  38 in total

1.  Residues of human cytomegalovirus DNA polymerase catalytic subunit UL54 that are necessary and sufficient for interaction with the accessory protein UL44.

Authors:  Arianna Loregian; Brent A Appleton; James M Hogle; Donald M Coen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 2.  Evolution of immunity: no development without risk.

Authors:  Alexander B Sigalov
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

3.  Cells diversify transmembrane signaling through the controlled chaos of protein disorder.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2011-04-01

4.  Topological side-chain classification of beta-turns: ideal motifs for peptidomimetic development.

Authors:  Tran Trung Tran; Jim McKie; Wim D F Meutermans; Gregory T Bourne; Peter R Andrews; Mark L Smythe
Journal:  J Comput Aided Mol Des       Date:  2005-11-23       Impact factor: 3.686

5.  Study of intra-inter species protein-protein interactions for potential drug targets identification and subsequent drug design for Escherichia coli O104:H4 C277-11.

Authors:  Shakhinur Islam Mondal; Zabed Mahmud; Montasir Elahi; Arzuba Akter; Nurnabi Azad Jewel; Md Muzahidul Islam; Sabiha Ferdous; Taisei Kikuchi
Journal:  In Silico Pharmacol       Date:  2017-04-11

6.  Statistical analysis of physical-chemical properties and prediction of protein-protein interfaces.

Authors:  Surendra S Negi; Werner Braun
Journal:  J Mol Model       Date:  2007-09-09       Impact factor: 1.810

7.  Computer aided design of FtsZ targeting oligopeptides.

Authors:  Stefano Rendine; Chacko Jobichen; Stefano Pieraccini; Prerna Domadia; J Sivaraman; Pierangelo Francescato; Giovanna Speranza; Maurizio Sironi
Journal:  RSC Adv       Date:  2012-12-21       Impact factor: 3.361

8.  The SCHOOL of nature: I. Transmembrane signaling.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-01

9.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

Review 10.  Computational and experimental approaches to chart the Escherichia coli cell-envelope-associated proteome and interactome.

Authors:  Juan Javier Díaz-Mejía; Mohan Babu; Andrew Emili
Journal:  FEMS Microbiol Rev       Date:  2008-11-27       Impact factor: 16.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.